8,882 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Icon Wealth Advisors LLC

Icon Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJFree Report) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 8,882 shares of the company’s stock, valued at approximately $1,392,000.

Several other large investors have also recently modified their holdings of JNJ. WealthPlan Investment Management LLC increased its stake in Johnson & Johnson by 495.4% during the 3rd quarter. WealthPlan Investment Management LLC now owns 67,728 shares of the company’s stock valued at $10,549,000 after purchasing an additional 56,352 shares in the last quarter. EagleClaw Capital Managment LLC increased its stake in Johnson & Johnson by 0.6% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 17,616 shares of the company’s stock valued at $2,744,000 after purchasing an additional 100 shares in the last quarter. ACR Alpine Capital Research LLC increased its stake in Johnson & Johnson by 3.2% during the 3rd quarter. ACR Alpine Capital Research LLC now owns 985,489 shares of the company’s stock valued at $153,490,000 after purchasing an additional 30,971 shares in the last quarter. Austin Private Wealth LLC increased its stake in Johnson & Johnson by 42.8% during the 3rd quarter. Austin Private Wealth LLC now owns 8,695 shares of the company’s stock valued at $1,354,000 after purchasing an additional 2,604 shares in the last quarter. Finally, Pinnacle West Asset Management Inc. increased its stake in Johnson & Johnson by 5.6% during the 3rd quarter. Pinnacle West Asset Management Inc. now owns 14,620 shares of the company’s stock valued at $2,277,000 after purchasing an additional 775 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Bank of America dropped their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. Finally, StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Monday. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $174.07.

View Our Latest Stock Analysis on JNJ

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $1.31 during mid-day trading on Tuesday, reaching $145.82. The company’s stock had a trading volume of 746,152 shares, compared to its average volume of 7,377,364. The stock has a 50-day moving average of $149.06 and a two-hundred day moving average of $154.88. The stock has a market capitalization of $350.94 billion, a P/E ratio of 9.18, a P/E/G ratio of 2.45 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.68 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.